Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells. 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Riviciclib hydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 12,800 | 8-10周 | ||
50 mg | ¥ 16,800 | 8-10周 | ||
100 mg | ¥ 21,500 | 8-10周 |
Riviciclib 的其他形式现货产品:
产品描述 | Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells. |
靶点活性 | CDK6-CyclinD1:0.396 μM, CDK2-CyclinE:2.540 μM, CDK1-CyclinB:0.079 μM, CDK2-CyclinA:0.224 μM, CDK9-CyclinH:2.900 μM, CDK4-CyclinD1:0.063 μM, CDK9-CyclinT1:0.020 μM |
体外活性 | Riviciclib (3-24 hours; 1.5 μM) reduces cyclin D1, Cdk4, and Rb levels in H-460 cells. Rb (retinoblastoma) phosphorylation at Ser780 decrease at 3 h. Riviciclib shows activity in human cancer cell lines, such as colon carcinoma, osteosarcomal, cervical carcinoma, and bladder carcinoma cells[2].Riviciclib shows no detectable cells in G1 and G2 in promyelocytic leukemia cells and arrest of cells in G1 in synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells[3]. |
体内活性 | Riviciclib in human xenograft mode with severe combined immunodeficient mice shows significant inhibition in the growth of human colon carcinoma HCT-116 xenograft[3]. |
别名 | P276-00 (free base) |
分子量 | 401.84 |
分子式 | C21H20ClNO5 |
CAS No. | 920113-02-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Riviciclib 920113-02-6 Others P276-00 (free base) P276-00 Inhibitor inhibitor inhibit